TG Therapeutics, Inc.'s BRIUMVI saw Q1 2025 revenue surge 137% YoY. Click to learn about TGTX growth, upcoming trials, and ...

Multiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory ...

People living with an autoimmune disease are nearly twice as likely to suffer from mood problems like depression, anxiety or ...

People are using cannabis for everything from pain to insomnia. Here’s when it might help and when it won’t. And don’t smoke ...

Children most affected by MS-related biological aging appeared to be aging up to two years faster than kids without MS, even ...

Before making changes to your diet, it’s a good idea to speak to your doctor or a qualified dietitian to make sure you don’t ...

Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market.

Yann Echelard, Director at TG Therapeutics TGTX , disclosed an insider sell on June 16, according to a recent SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange ...

Also known as colour vision deficiency (CVD), the condition is said to affect three million people in the UK alone, working ...

Synthetic food dyes are added to 1 in 5 packaged foods and drinks sold by top U.S. food manufacturers, a new study says.

Indian pharma speeds up access to global therapies while targeting treatment gaps: Nandita Vijayasimha, Bengaluru Saturday, June 28, 2025, 08:00 Hrs [IST] Indian pharma is now agg ...